TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03211949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary block
Description: 2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scandicaine
Description: 2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
Study: NCT01343563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trigeminal Nerve Stimulation
Description: External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
Study: NCT00413283

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion
Study: NCT02144883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help materials
Description: All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help materials
Description: All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
Study: NCT00778609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027)
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Encapsulated Microgynon + Placebo
Description: Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
Study: NCT06501521

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
Study: NCT00695864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron and Placebo crossover
Study: NCT06501521

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
Study: NCT02972658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally
Study: NCT01626833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOMATROPINE* : Norditropine® simplexx®
Description: SOMATROPINE\* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
Study: NCT01377844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGT0001442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00549666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg
Description: Lurasidone 40 mg days 12-21 once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 40 mg
Description: Placebo 40 mg once daily during treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen
Description: Ortho Tri-Cyclen during 28-day lead in period
Study: NCT03072745

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
Study: NCT05168345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Course and web information
Description: The interventional phase of the study will be conducted on IBD patients only. Patients will undergo two interventional periods which will include:~1. Self-selected information from the internet - patients will be asked to independently search the web for information regarding the categories of information which are discussed in the online course.~2. An online, interactive IBD course. Lectures will be passed by the multidisciplinary team of the IBD Center which includes IBD gastroenterologists, an IBD nurse, an IBD dietitian, and a social worker.
Study: NCT02876653

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography , blood collection, bone densitometry and Functional respiratory explorations
Description: Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography , blood collection, bone densitometry and Functional respiratory explorations
Description: Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers

Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography , blood collection, bone densitometry and Functional respiratory explorations
Description: Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers
Study: NCT03937089

Intervention type: OTHER
Intervention: Data collection
Description: Data collection from medical file
Study: NCT01331278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty with Custom Cutting Blocks
Description: Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty via Computer Assisted Surgery
Description: Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
Study: NCT03185143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acetaminophen Combination
Description: Treat a single Qualified Migraine attack.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan 100 mg
Description: One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
Study: NCT01307306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin R
Description: Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
Study: NCT03720249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation of compound nutrients
Description: Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
Study: NCT00433706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control position by 3DOBI before the fraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard imaging
Study: NCT00695864

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron and Placebo crossover
Study: NCT00994851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENNA+CASSIA
Description: Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
Study: NCT04641052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: The music type will be chosen by the patients and researchers will not have any influence on their choices.
Study: NCT03111368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided fine needle aspiration
Description: pancreatic solid mass punctured with a 22G endoscopic ultrasound needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided fine needle aspiration
Description: pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
Study: NCT03890653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-Based Financing
Description: Incentive-based payments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decentralized Facility Financing
Description: Financing not linked to service delivery.
Study: NCT01336842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat, Cisplatin, Pemetrexed
Description: Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1.
Study: NCT01754571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Behavior therapy, including Relaxation, cognitive rebuilding.
Study: NCT01894022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Description: Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
Study: NCT03760679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask Supreme evaluation
Description: Device: Laryngeal mask Supreme evaluation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel evaluation
Description: Device: i-gel evaluation
Study: NCT04314011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells（HUC-MSCs）
Description: Human umbilical cord mesenchymal stem cells（HUC-MSCs）

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02486965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermode (TSA-II model)
Description: thermal stimulation with test thermode

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adapted Physical Activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Study: NCT02651220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo® Forte Gel
Description: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl Peroxide Gel
Description: Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: vehicle used as placebo
Study: NCT01272765

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHBG-10
Description: 500 mg IHBG-10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHBG-10
Description: 500 mg IHBG-10

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHBG-10
Description: 500 mg IHBG-10
Study: NCT03327194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHEAR Audio Processor
Description: ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark.
Study: NCT00794885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril/folic acid
Description: Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril maleate
Description: Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
Study: NCT01984996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom ProFlor Inguinal Hernia Implant
Study: NCT03363880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trauma treatment team
Description: Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic experimental settings
Description: Establishing the trauma management system without a trauma treatment team.
Study: NCT03492801

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04038567

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile mindfulness-based training
Description: The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile mindfulness-based training
Description: The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile mindfulness-based training
Description: The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile mindfulness-based training
Description: The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile mindfulness-based training
Description: The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile mindfulness-based training
Description: The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 6 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
Study: NCT02772185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real CT
Description: Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real CT
Description: Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: placebo CT
Description: Videos (short films) will be presented during the neurostimulation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo CT
Description: Videos (short films) will be presented during the neurostimulation